Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas - PubMed (original) (raw)

. 1991 May;138(5):1059-67.

Affiliations

PMID: 1850957
PMCID: PMC1886028

Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas

C Pyke et al. Am J Pathol. 1991 May.

Abstract

In this study in situ hybridization methods were used to examine biopsy samples from 13 adenocarcinomas of the colon for the presence of mRNA for the urokinase-type plasminogen activator (u-PA) and its specific cell-surface receptor (u-PAR). In all cases, u-PA mRNA was present in fibroblastlike cells in the stroma adjacent to the invasive tumor nodules. Urokinase-type plasminogen activator mRNA was not detected in the malignant cells. All specimens also contained u-PAR mRNA in cells located at the tumoral-stromal interface of invasive foci, but in contrast at least some of these cells were in all but one case identified as being of malignant origin. Stromal cells, probably tumor-infiltrating macrophages and neutrophils, also were positive in these areas. These results support the view that components of the plasminogen activation system may act to influence proteolytic events occurring at the interface between stroma and malignant cells in adenocarcinomas of the colon in humans.

PubMed Disclaimer

Cited by

Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.
El Salamouni NS, Buckley BJ, Ranson M, Kelso MJ, Yu H. El Salamouni NS, et al. Biophys Rev. 2022 Jan 6;14(1):277-301. doi: 10.1007/s12551-021-00921-7. eCollection 2022 Feb. Biophys Rev. 2022. PMID: 35340592 Free PMC article. Review.
Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma.
Tincknell G, Piper AK, Aghmesheh M, Becker T, Vine KL, Brungs D, Ranson M. Tincknell G, et al. Cancers (Basel). 2021 Aug 14;13(16):4097. doi: 10.3390/cancers13164097. Cancers (Basel). 2021. PMID: 34439251 Free PMC article. Review.
The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Brungs D, Chen J, Aghmesheh M, Vine KL, Becker TM, Carolan MG, Ranson M. Brungs D, et al. Oncotarget. 2017 Apr 4;8(14):23099-23109. doi: 10.18632/oncotarget.15485. Oncotarget. 2017. PMID: 28416743 Free PMC article. Review.
Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma.
Tian B, Chen X, Zhang H, Li X, Wang J, Han W, Zhang LY, Fu L, Li Y, Nie C, Zhao Y, Tan X, Wang H, Guan XY, Hong A. Tian B, et al. Oncotarget. 2017 Jun 27;8(26):42300-42313. doi: 10.18632/oncotarget.15857. Oncotarget. 2017. PMID: 28404945 Free PMC article.
Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine.
Gouri A, Dekaken A, El Bairi K, Aissaoui A, Laabed N, Chefrour M, Ciccolini J, Milano G, Benharkat S. Gouri A, et al. Biomark Insights. 2016 Aug 16;11:105-11. doi: 10.4137/BMI.S33372. eCollection 2016. Biomark Insights. 2016. PMID: 27578963 Free PMC article. Review.

References

1. Am J Pathol. 1991 Jan;138(1):111-7 - PubMed
1. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7 - PubMed
1. Cancer Res. 1990 Nov 1;50(21):6827-9 - PubMed
1. J Cell Biol. 1988 Sep;107(3):1199-205 - PubMed
1. J Cell Biol. 1989 May;108(5):1987-95 - PubMed

Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas - PubMed (original) (raw)